EUVIMEDEUVIMED entdecken
Open Access

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection

Pengpeng Li, Yuanyuan Wang, Jian Yu, Judian Yu, Qifei Tao, Jinwei Zhang, Wan Yee Lau, Weiping Zhou, Gang Huang

JAMA Network Open · 31.10.2023 · 6 (10) · e2340353

DOI: 10.1001/jamanetworkopen.2023.40353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 31.10.2023. Verfasst von Pengpeng Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Third Affiliated Hospital of Naval Medical University, Eastern Hepatobiliary Surgery Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Tenofovir disoproxil and entecavir are both commonly used first-line antiviral treatments, but their comparative recurrence and overall survival (OS) benefits remain unclear.

Objective

To explore differences of tenofovir disoproxil vs entecavir in recurrence-free survival (RFS) and OS after liver resection with curative intent in patients with hepatocellular cancer (HCC) related to hepatitis B virus (HBV). Design, Setting, and Participants This retrospective cohort study was conducted at Eastern Hepatobiliary Surgery Hospital, a tertiary referral hospital in Shanghai, China, between January 4, 2015, and April 1, 2023. Participants included patients with HBV-related HCC who underwent liver resection with curative intent from January 2015 to December 2018. Patients who received tenofovir disoproxil were matched with patients who received entecavir in a 1:1 ratio using propensity score matching. Data were analyzed from April 3 to May 31, 2023. Exposures Receiving tenofovir disoproxil or entecavir as antiviral treatment for HBV. Main Outcomes and Measures Primary end points were RFS and OS rates.

Results

Among 4451 patients (mean [SD] age, 58.1 [10.0] years; 3764 male [84.6%]; median [range] follow-up, of 51 [3 to 91] months), 989 patients in each of the groups were selected in propensity score matching. Baseline characteristics were comparable. In propensity score–matched groups, OS rates were 92.2% at 1 year, 70.9% at 3 years, and 54.2% at 5 years in the entecavir group, compared with 90.9% at 1 year, 75.2% at 3 years, and 64.0% at 5 years in the tenofovir disoproxil group. RFS rates were 83.9% at 1 year, 50.0% at 3 years, and 43.3% at 5 years in the entecavir group, compared with 85.3% at 1 year, 55.6% at 3 years, and 51.4% at 5 years in the tenofovir disoproxil group. Patients in the tenofovir disoproxil group had better OS (hazard ratio, 0.82; 95% CI, 0.72 to 0.94; P = .004) and RFS rates (hazard ratio, 0.81; 95% CI, 0.72 to 0.92; P = .001) compared with the entecavir group. Restricted mean survival time differences of entecavir vs tenofovir disoproxil groups were −0.05 (95% CI, −0.18 to 0.08) months at 1 year ( P = .45), 0.20 (95% CI, −0.62 to 1.03) months at 3 years ( P = .63), and 1.82 (95% CI, 0.14 to 3.51) months at 5 years ( P = .03). Conclusions and Relevance These findings suggest that in patients undergoing curative liver resection for HBV-related HCC, tenofovir disoproxil was associated with better long-term OS and RFS rates compared with entecavir, providing insights for antiviral treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansMaleMiddle AgedHepatitis B virusTenofovirRetrospective StudiesChinaTertiary Care CentersAntiviral AgentsGuanine

Substanzen

TenofovirAntiviral AgentsentecavirGuanine

Autor:innen und Institutionen

  • Third Affiliated Hospital of Naval Medical University, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Faculty of Medicine, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Special Administrative Region, People's Republic of China.

Zitieren

APA

Li, P., Wang, Y., Yu, J., Yu, J., Tao, Q., Zhang, J., Lau, W. Y., Zhou, W., & Huang, G. (2023). Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection. JAMA Network Open, 6(10), e2340353. https://doi.org/10.1001/jamanetworkopen.2023.40353

Vancouver

Li P, Wang Y, Yu J, Yu J, Tao Q, Zhang J, et al. Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection. JAMA Network Open. 2023;6(10):e2340353. doi:10.1001/jamanetworkopen.2023.40353

BibTeX
@article{Li2023,
  author = {Li, Pengpeng and Wang, Yuanyuan and Yu, Jian and Yu, Judian and Tao, Qifei and Zhang, Jinwei and Lau, Wan Yee and Zhou, Weiping and Huang, Gang},
  title = {Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {10},
  pages = {e2340353},
  doi = {10.1001/jamanetworkopen.2023.40353}
}
Kostenlos starten →